StocksMediumUpdated•Originally published 10 November 2026•Updated 10 November 2026•
1 min read
Corbus Pharmaceuticals Reports Zero Revenue and Wider Q3 Loss
Key Facts
1Corbus Pharmaceuticals reported a GAAP EPS loss of $1.81, missing analyst estimates by $0.48.
Corbus Pharmaceuticals reported $0 in revenue for the third quarter of 2026, missing analyst expectations of $1.275 million. Seeking Alpha reported that the company also posted a GAAP EPS loss of $1.81, which was $0.48 wider than market consensus for the period ending September 2026.
CRBP closed at $3.52 on November 9, 2026, as financial disclosures showed the company held $115.3 million in cash, cash equivalents, and investments as of September 30, 2026. Management expects these cash reserves to fund planned operations into 2028.